Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Kazia Therapeutics will raise $4 million through an institutional placement to improve two drug candidates for treating various cancers
  • 10 million fully paid ordinary shares have been allocated to institutional, professional and sophisticated investors at $0.40 cents per new share
  • Settlement of the placement is expected to occur by the end of the month
  • Kazia’s shares are down 3.23 per cent, with shares trading at 45 cents each

Kazia Therapeutics will raise $4 million to improve its GDC-0084 and Cantrixil cancer programs.

Under the placement, 10 million fully paid ordinary shares have been allocated to institutional, professional and sophisticated investors at $0.40 cents per new share.

Kazia is an innovative oncology-focused biotech company that is currently developing GDC-0084 and TRX-E-002-1 (Cantrixil).

Kazia Chairman Iain Ross is pleased by the strong interest received regarding the placement.

“It is testament to the Company’s growing credibility and prospects that this round has been performed at a premium to our last round, and without the need for warrants, convertible notes, or similar arrangements, and was oversubscribed,” Iain said.

The GDC-0084 novel target therapy is being developed to treat glioblastoma multiforme which is the most common and most aggressive form of primary brain cancer in adults.

The drug candidate entered a phase II clinical trial in 2018 and initial safety data was released in May 2019.

Kazia plans to present further interim clinical data from its ongoing trial at the Society for Neuro-Oncology (SNO) annual meeting in Phoenix, Arizona on November 20-24 2019.

Cantrixil is a third-generation benzopyran molecule that is being developed to treat ovarian cancer. It is currently undergoing a phase I clinical trial in Australia and the United States.

Interim data was presented last month at the ESMO Congress, a global stage for excellence in cancer research, practice-changing data and multidisciplinary discussions.

Cantrixil was granted orphan designation by the U.S. FDA in April 2015, while GDC-0084 was granted orphan designation in February last year.

Settlement of the placement is expected to occur on or around October 31 2019.

Kazia’s shares are down 3.23 per cent, with shares trading at 45 cents each at 3:11 pm AEDT.

KZA by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - MD and CEO Phillip Lynch

" Race Oncology (ASX:RAC) secures sixth US patent for Zantrene

Race Oncology (RAC) has locked in its sixth US patent for its cancer drug, Zantrene.
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.